William Blair Forecasts Amedisys' Q1 Earnings (NASDAQ:AMED)

Amedisys, Inc. (NASDAQ:AMED - Free Report) - Investment analysts at William Blair reduced their Q1 2025 EPS estimates for shares of Amedisys in a research report issued to clients and investors on Thursday, February 27th. William Blair analyst M. Larew now forecasts that the health services provider will earn $0.98 per share for the quarter, down from their prior forecast of $1.01. The consensus estimate for Amedisys' current full-year earnings is $4.40 per share. William Blair also issued estimates for Amedisys' Q2 2025 earnings at $1.33 EPS, Q3 2025 earnings at $1.05 EPS, Q4 2025 earnings at $1.08 EPS and FY2025 earnings at $4.45 EPS.

Separately, Stephens reaffirmed an "equal weight" rating and set a $101.00 price target on shares of Amedisys in a research note on Tuesday. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, Amedisys has an average rating of "Hold" and a consensus price target of $100.75.

Amedisys Price Performance

AMED traded up $0.10 during trading on Friday, reaching $92.10. 227,711 shares of the stock were exchanged, compared to its average volume of 379,715. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The company has a market capitalization of $3.02 billion, a price-to-earnings ratio of 36.55, a P/E/G ratio of 1.78 and a beta of 0.73. Amedisys has a 1 year low of $82.15 and a 1 year high of $98.95. The business's 50 day moving average price is $91.55 and its two-hundred day moving average price is $93.10.

Remove Ads

Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing the consensus estimate of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm had revenue of $598.05 million for the quarter, compared to analysts' expectations of $602.38 million.

Hedge Funds Weigh In On Amedisys

A number of institutional investors have recently made changes to their positions in AMED. National Bank of Canada FI boosted its stake in shares of Amedisys by 119.0% during the third quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider's stock valued at $5,365,000 after acquiring an additional 30,213 shares during the last quarter. ABC Arbitrage SA acquired a new stake in shares of Amedisys during the 4th quarter worth about $2,522,000. Geode Capital Management LLC grew its holdings in shares of Amedisys by 1.3% during the third quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider's stock worth $54,746,000 after buying an additional 7,071 shares in the last quarter. Quarry LP purchased a new stake in shares of Amedisys during the third quarter worth about $2,569,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Amedisys by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider's stock valued at $33,400,000 after buying an additional 9,004 shares during the last quarter. 94.36% of the stock is owned by institutional investors and hedge funds.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.